Aventis, part of the sanofi-aventis Group, announced today that it had sent to Genta a notice of termination of the agreements entered into by the two companies in 2002 and concerning the development of Genasense® (oblimersen sodium). At the time the agreements with Genta were entered into, Aventis was seeking a late-stage development opportunity that could potentially provide for a near term
~ First Major Advance in the Postsurgical Treatment Of Early-Stage Colon Cancer in More Than a Decade ~ Sanofi-Synthelabo, a member of the sanofi-aventis Group announced today that the US Food and Drug Administration (FDA) has approved ELOXATIN, in combination with conventional chemotherapy (infusional 5-fluorouracil/leucovorin, known as 5-FU/LV), for the adjuvant (postsurgical) treatment of
Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere®(docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen independent (hormone-refractory) metastatic prostate cancer. The Commission approval is based on the results of a large landmark phase III clinical trial, TAX 327, which demonst
Behovet av BPH-relaterad kirurgi reduceras Resultaten av ALFAUR-studien (ALFuzosin in Acute Urinary Retention), som presenterades vid European Association of Urologys (EAU) kongress i Wien, visar att den uroselektiva alfa1-blockeraren alfuzosin 10 mg en gång dagligen (OD = once daily) kan ha en positiv effekt på behandlingen av män som lider av akut urinretention (AUR). Akut urinretention (u
En ny studie ska ge svar på hur en vanlig form av hjärtsvikt kan behandlas. Ungefär hälften av alla patienter med hjärtsvikt har en normal sk. systolisk funktion.
Sanofi-Synthelabo AB har förstärkt verksamheten genom att tillsätta Tommy Olin som operativ chef.